Technical analysis of Enveric Biosciences, Inc. (ENVB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application.
Price Performance
| 1 month | +10.37% |
| 3 months | +16.41% |
| Year-to-date | -58.95% |
| 1 year | -80.80% |
| 3 years | -99.64% |
| 5 years | -99.99% |
52-Week Range
| 52-week High | $13.25 |
| 52-week Low | $1.17 |
| Avg Volume (90d) | 152K |
Technical Indicators
| SMA 50 | $1.43 |
| SMA 200 | $2.59 |
| 30-day Volatility (annualised) | 53.6% |
| Price vs SMA 50 | +4.5% |
| Price vs SMA 200 | -42.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.70 | |
| 2025-11 | $5.74 | +0.7% |
| 2025-12 | $3.63 | -36.8% |
| 2026-01 | $2.91 | -19.8% |
| 2026-02 | $2.35 | -19.2% |
| 2026-03 | $1.94 | -17.4% |
| 2026-04 | $3.95 | +103.6% |
| 2026-05 | $2.30 | -41.8% |
| 2026-06 | $1.38 | -40.0% |
| 2026-07 | $1.57 | +13.8% |
| 2026-08 | $1.37 | -12.7% |
| 2026-09 | $1.49 | +8.8% |
Price
| Price | $1.49 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.74 |
| EV / EBITDA | 0.87 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 10.21 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -35.49 |